The Society of Chemical Manufacturers and Affiliates (SOCMA) will affiliate Bio-Process Systems Alliance (BPSA), an industry trade group that promotes the implementation of single-use biopharmaceutical manufacturing technologies. Joseph
Cardio3 BioSciences has completed enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a stem cell therapy for heart failure. The enrollment was completed
Biovitrum has announced that the first patient was dosed in a Phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIIIFc) protein. The Phase I/IIa open-label
US-based Alvogen has established operations in Asia and has opened an office in Shanghai, China that will lead efforts to commercialize the company’s products in the country. Alvogen
Lytix Biopharma has announced approvals from the Norwegian Medicines Agency (Statens legemiddelverk) and the Swedish Medical Products Agency (Lakemedelverket) to commence Phase I clinical trials of Oncopore (LTX-315)
Human Genome Sciences (HGS) has announced that Novartis has submitted a Marketing Authorization Application (MAA) to the EMEA for approval to market Joulferon (albinterferon alfa-2b, known in the
The US Patent and Trademark Office (USPTO) has issued a notification to NovaDel Pharma (NovaDel) for a new US Patent No. 7632517, entitled Buccal, Polar and Non-polar Spray
Amylin Pharmaceuticals (Amylin), Eli Lilly and Alkermes have reported positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to Byetta (exenatide) injection taken
AstraZeneca and the University of Virginia (UVa) have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD), with a
Repligen has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich’s ataxia from the Muscular Dystrophy Association (MDA). The company said that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.